NCT03519750View on ClinicalTrials.gov

Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

February 21, 2019

Study Completion Date

February 21, 2019

Conditions
MelatoninPharmacokineticsSafety
Interventions
DRUG

Melatonin 25 mg

24-48 hour monitoring of plasma melatonin as well as adverse events.

Trial Locations (1)

2000

Herlev Hospital, Herlev

All Listed Sponsors
collaborator

Copenhagen University Hospital, Denmark

OTHER

collaborator

RepoCeuticals ApS

UNKNOWN

collaborator

Herlev Hospital

OTHER

lead

Dennis Bregner Zetner

OTHER

NCT03519750 - Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers | Biotech Hunter | Biotech Hunter